Eugene Sefanov

  If there’s one company that believes in the digital health revolution, it’s LEO Pharma. According to news sources and a press release from the Denmark-based company, last year LEO Pharma invested $3.4M in SkinVision, the developer of a mobile app that helps detect melanoma, a serious form of skin cancer. Simply snap a picture […]

  Have you heard? Some retail establishments, in countries like the Netherlands, don’t accept cash anymore. As I mentioned in a previous post, digital money is making big waves – everywhere. While it’s starting to make a serious dent in the United States, the use of mobile payments are much more widespread in other countries. […]

  Risk-based monitoring (RBM) continues to be a hot topic among sponsors and contract research organizations (CROs) for a variety of reasons, including the time- and cost-savings it can offer, as well as its ability to help keep patients safe. Last week, Ashok Ghone, Ph.D., vice president of global services at MakroCare USA, wrote a […]

  Several days ago, I wrote about how the life sciences industry, including government organizations, is struggling when it comes to the reporting of clinical trial results to the ClinicalTrials.gov database. Unfortunately, other issues plague the industry, including one that The New York Times reported on January 14, 2016. The Government Accountability Office (GAO) found […]

  According to IBM, we generate 2.5 quintillion bytes of data every day. And, 90% of the data that exists today, whether found in your clinical systems, on social media, or on your mobile devices, has been gathered within the last two years. All of that is what we call “big data.” As the volume […]

  In the good ol’ days, walking in the clinic door and asking for a few minutes of a physician’s time was the main method used by sales reps to position a drug in the doctor’s mind. Physician outreach was, and still is, one of the most effective ways to penetrate the market with a […]

  The life sciences industry could learn a little something from Southwest Airlines’ “Transfarency” campaign, in terms of reporting clinical trial results. A recent investigation by the publication STAT found significant violations in the reporting of clinical trial results to the ClinicalTrials.gov database. Most academic research institutions, drug companies, and even the National Institutes of […]

  So, one of my spunky co-workers, who happens to be the prolific blogger behind www.adviceformydaughter.com, shared this on Facebook: “My daughter wants to use her Christmas money to buy a diabetes kit, just like daddy’s, for her American Girl Doll. It makes me happy that she will understand this part of his life a […]

  An interesting thing happened in pharma and investing. It involved Regeneron and their July 24, 2015 FDA-approved cholesterol drug, Praluent. Forbes outlined the situation, which caused Regeneron stock to drop significantly, in a January 6, 2016 article. According to Matthew Herper, a Forbes columnist, investors got a hold of data from the FDA’s Adverse […]

  Last week, I wrote that Vice President Joe Biden was going to meet with cancer researchers to talk about regulatory questions revolving around precision medicine. Today, we know much more about the cancer “moonshot” President Obama charged Biden with in this week’s State of the Union address. In a post on the publishing platform […]

  In case you missed the headlines, Mark Zuckerberg and Priscilla Chan got the best Thanksgiving gift ever last year – their daughter. Her name is Max. The proud parents wrote a breathtaking letter to her, sharing images of the world she lives in today and what they hope Max grows up to see. Just […]

  I really don’t like carrying cash. And, the only reason I do is because that’s all my barber accepts. I prefer using digital money. Huh, digital money? According to Investopedia, digital money is “any means of payment that exists purely in electronic form.” In other words, think of digital money as using any payment […]